Injenia Therapeutics and Gido Sanup will be listed in turn on the 18th and 21st, respectively, while SkyLabs will conduct a private placement for institutional investors by the 21st.
Injenia Therapeutics is a U.S.-based biotech firm headquartered in Boston that develops treatments for cardiovascular disease based on its proprietary cell‑regeneration technology. The company’s domestic listing will be conducted through a DR (direct registration) method, with Samsung Securities acting as the lead manager. Through this offering, the firm plans to fund research and development of new pipeline candidates beyond those already in phase III testing.
Gido Sanup is an original equipment manufacturer (OEM) and original design manufacturer (ODM) that produces and supplies motor‑cycle and other automotive components. Its major customers include Harley‑Davidson, Barbour, Jackulphskin, Sheple and others. In the last fiscal year, revenue was KRW 346.6 billion with operating profit of KRW 32.2 billion; sales have averaged a 24% annual growth over the past three years.
SkyLabs is a company that has been established mainly for developing wearable medical devices. Its flagship product, “Cardi‑BIP Pro,” is an instrument that measures heart rate and blood pressure continuously for 24 hours by wearing a cuff‑like device on the wrist. In the last year, sales were KRW 7.9 billion, which doubled from the prior year, expanding operating profit as well.
The current IPO market is focused more on listing dates than on other factors. Injenia Therapeutics and Gido Sanup will be listed in turn on the 18th and 21st respectively, while SkyLabs will conduct a private placement for institutional investors by the 21st.